GlassScriptPhysician profile
Saeed Zafar
NPI 1386671659
$1,931.44
in general payments reported to CMS, 2019-2025
21 companies · $488 in 2025
The $488 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $229 · 2021: $72.80 · 2022: $113 · 2023: $496 · 2024: $384 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.12 |
| Education | $137.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $294.55 | 2019-2024 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $209.31 | 2021-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $186.88 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $151.60 | 2023-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $132.42 | 2019-2024 | Velphoro, Korsuva |
| Amgen INC. | $130.43 | 2019-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $114.07 | 2021-2025 | |
| Travere Therapeutics, INC. | $89.65 | 2020-2025 | Filspari |
| Akebia Therapeutics INC | $82.78 | 2020-2024 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $81.30 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $76.65 | 2020-2023 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.05 | 2022 | |
| Fresenius USA Manufacturing, INC. | $65.31 | 2025 | |
| Novo Nordisk INC | $56.38 | 2025 | Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $46.96 | 2025 | Lupkynis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $34.06 | 2024 | Defencath |
| Lilly USA, LLC | $32.38 | 2023-2025 | Jardiance |
| Chiesi USA, INC. | $25.98 | 2025 | Mycapssa |
| Glaxosmithkline, LLC. | $22.95 | 2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $16.81 | 2020 | |
| Mallinckrodt Enterprises LLC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeed Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.